JNJ vs AMGN Comparison: AI Score, Valuation, Performance and Upside
Compare Johnson & Johnson's broad-based pharma and medtech portfolio against Amgen's biosimilar franchise and early-stage obesity drug pipeline (MariTide).
Use this Johnson & Johnson vs Amgen comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
AMGN holds the edge across 3 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+50.62% vs +36.90%), though AMGN has the better forward P/E setup (15.46x vs 21.78x for JNJ). AMGN leads on both revenue growth (9.50%) and operating margin (35.55%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +1.66% for JNJ and +2.83% for AMGN.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | JNJ | AMGN |
|---|---|---|
| AI scorei | 49.9 | 49.6 |
| AI ranki | #553 | #566 |
| Latest closei | $267.20 | $375.65 |
| 1M returni | +2.63% | -9.53% |
| 6M returni | +12.22% | +4.02% |
| 1Y returni | +50.62% | +36.90% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | JNJ | AMGN |
|---|---|---|
| 1Y ago | $15.14K (+51.4%) started 2025-09-16 | $13.76K (+37.6%) started 2025-09-16 |
| 5Y ago | $19.96K (+99.6%) started 2021-09-17 | $21.93K (+119.3%) started 2021-09-17 |
| 10Y ago | $37.29K (+272.9%) started 2016-09-19 | $38.43K (+284.3%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | JNJ | AMGN |
|---|---|---|
| Market capi | $645.95B | $204.01B |
| Trailing P/Ei | 31.06 | 23.42 |
| Forward P/Ei | 21.78 | 15.46 |
| Price/Salesi | 4.18 | 4.57 |
| EV/Revenuei | 6.88 | 6.49 |
| Analyst targeti | $272.50 | $388.03 |
| Target upsidei | +1.66% | +2.83% |
| Metric | JNJ | AMGN |
|---|---|---|
| Revenue growthi | 6.60% | 9.50% |
| Earnings growthi | -0.90% | 64.90% |
| EPS growthi | -0.90% | +64.90% |
| FCF margini | +17.24% | +22.69% |
| Operating margini | 29.19% | 35.55% |
| Profit margini | 21.48% | 22.95% |
| ROIC proxyi | 25.74% | 91.47% |
| Return on equityi | 25.74% | 91.47% |
| Dividend yieldi | 2.00% | 2.64% |
| Payout ratioi | 60.79% | 60.87% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.23 | 0.43 |
| Debt/equityi | 57.71 | 490.28 |
| Current ratioi | 1.09 | 1.37 |
| Quick ratioi | 0.72 | 0.95 |
Over the past year, JNJ and AMGN have moved moderately in the same direction (correlation of 0.42), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | JNJ | AMGN |
|---|---|---|---|
| 1Y | Growthi | +51.42% | +37.56% |
| CAGRi | +51.55% | +37.64% | |
| Volatilityi | 19.11% | 29.45% | |
| Sharpe ratioi | 2.04 | 1.08 | |
| Sortino ratioi | 3.24 | 1.69 | |
| Max drawdowni | 10.96% | 16.57% | |
| Current drawdowni | 4.03% | 15.42% | |
| Avg drawdowni | 2.94% | 5.52% | |
| Ulcer Indexi | 4.12% | 7.33% | |
| Max daily dropi | 3.66% | 10.08% | |
| Max wkly dropi | 6.22% | 15.03% | |
| 5Y | Growthi | +79.51% | +93.09% |
| CAGRi | +12.42% | +14.07% | |
| Volatilityi | 17.61% | 24.68% | |
| Sharpe ratioi | 0.50 | 0.48 | |
| Sortino ratioi | 0.74 | 0.71 | |
| Max drawdowni | 18.41% | 24.86% | |
| Current drawdowni | 4.03% | 15.42% | |
| Avg drawdowni | 7.01% | 8.17% | |
| Ulcer Indexi | 8.57% | 10.32% | |
| Max daily dropi | 7.59% | 10.08% | |
| Max wkly dropi | 9.18% | 15.03% | |
| 10Y | Growthi | +186.90% | +185.07% |
| CAGRi | +11.13% | +11.05% | |
| Volatilityi | 18.84% | 25.22% | |
| Sharpe ratioi | 0.42 | 0.36 | |
| Sortino ratioi | 0.59 | 0.53 | |
| Max drawdowni | 27.37% | 24.86% | |
| Current drawdowni | 4.03% | 15.42% | |
| Avg drawdowni | 6.41% | 8.22% | |
| Ulcer Indexi | 7.97% | 10.06% | |
| Max daily dropi | 10.04% | 10.08% | |
| Max wkly dropi | 13.25% | 15.79% |
| Category | JNJ | AMGN |
|---|---|---|
| Company | JNJ | AMGN |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.